Roche's Phase 3 Data Show Lymphoma Treatment Can Reduce Disease Risks

By Mauro Orru

Roche Holding AG presented new data from a Phase 3 study showing that its Polivy antibody-drug can significantly reduce the risk of disease deterioration or death for people with untreated diffuse large B-cell lymphoma.

The Swiss pharmaceutical company said Monday that most patients with the untreated disease that received Polivy in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, or rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, reported clinically meaningful improvements in lymphoma symptoms after the first cycle of treatment.

"These updated Polarix data indicate the potential benefits that this Polivy based-regimen could bring to people living with this aggressive type of lymphoma, and demonstrate our commitment to developing new treatment options," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.

Polivy is currently marketed in the European Union for the treatment of relapsed or refractory diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.

Separately, Roche on Sunday unveiled new data from a Phase 3 study in China showing that the crovalimab antibody is well-tolerated in people with paroxysmal nocturnal haemoglobinuria, an ultra-rare and life-threatening blood condition. The study met its primary efficacy endpoints of transfusion avoidance and haemolysis control.

The company also presented interim Phase 3 data showing that Hemlibra achieved meaningful bleed control with a favorable safety profile in infants of up to 12 months with severe haemophilia A, an inherited, serious disorder in which blood doesn't clot properly.

Write to Mauro Orru at [e-mail]; @MauroOrru94

(END) Dow Jones Newswires

December 12, 2022 02:11 ET (07:11 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.